›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:MammaPrint
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AgendiaType:
FDA Approved
Related tests:
Evidence Level:
Sensitive: C3 – Early Trials
[HR positive-HER2 Negative Breast Cancer-pembrolizumab]
Source:
Test:
MammaPrint
Title:
The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.
Published date:
05/26/2022
Excerpt:
Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup….In the signature development phase, ImPrint predicts pCR to Pembrolizumab in a set of 69 high risk EBC with high sensitivity and specificity.
DOI:
10.1200/JCO.2022.40.16_suppl.514
Evidence Level:
Sensitive: C3 – Early Trials
[HR positive-HER2 Negative Breast Cancer-olaparib + durvalumab]
Source:
Test:
MammaPrint
Title:
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Published date:
06/17/2021
Excerpt:
...(durvalumab/olaparib/paclitaxel [DOP])...DOP increased pathologic complete response (pCR) rates in all HER2-negative (20%–37%), hormone receptor (HR)-positive/HER2-negative (14%–28%), and triple-negative breast cancer (TNBC) (27%–47%)....DOP has superior efficacy over standard neoadjuvant chemotherapy in HER2-negative breast cancer, particularly in a highly sensitive subset of high-risk HR-positive/HER2-negative patients.
Secondary therapy:
paclitaxel
DOI:
https://doi.org/10.1016/j.ccell.2021.05.009
Trial ID:
